Literature DB >> 31798872

High-resolution melting for detecting KRAS mutations in colorectal cancer.

Raelson Rodrigues Miranda1, Tiago Donizetti Silva1, Nora Manoukian Forones1.   

Abstract

Colorectal cancer is a leading cause of cancer that may metastasize. KRAS gene sequence of exon 2 should be examined for identification of patients that can be treated with anti-EGFR. The aim of the present study was to evaluate the efficacy of high-resolution melting (HRM) to detect KRAS mutations in colorectal cancer (CRC) tumors. The exon 2 of KRAS was amplified from 47 adenocarcinoma CRC tissues. The tumors were subjected to high-resolution melt using quantitative PCR to identify wild-type and mutant subgroups. The results were compared to the mutations detected by next-generation sequences (NGS). The study included 47 patients, with a mean age of 62 years, of whom 24 patients were male. Most of the patients had stage II or stage III tumors. The mean melting temperatures for the wild-type and mutated group at exon 2 were 78.13˚C and 77.87˚C, respectively (P<0.001, 95% CI = 0.11-0.4). The sensitivity and specificity of high-resolution melting were 83.3 and 96.6%, respectively, with a high concordance between the NGS and HRM methods for detecting KRAS mutation in exon 2 (ĸ = 0.816; P=0.625). Thus, HRM could be used as an alternative method for detecting KRAS mutations in colorectal cancer tissue.
Copyright © 2019, Spandidos Publications.

Entities:  

Keywords:  DNA melting; DNA mutational analysis; K-ras gene; colorectal cancers; quantitative PCR

Year:  2019        PMID: 31798872      PMCID: PMC6873417          DOI: 10.3892/br.2019.1254

Source DB:  PubMed          Journal:  Biomed Rep        ISSN: 2049-9434


  23 in total

1.  Detection of KRAS mutations in colorectal cancer by high-resolution melting analysis.

Authors:  E S K Ma; C L P Wong; F B F Law; W-K Chan; D Siu
Journal:  J Clin Pathol       Date:  2009-10       Impact factor: 3.411

2.  High-throughput screening of extended RAS mutations based on high-resolution melting analysis for prediction of anti-EGFR treatment efficacy in colorectal carcinoma.

Authors:  Takayuki Ishige; Sakae Itoga; Kenichi Sato; Kouichi Kitamura; Motoi Nishimura; Setsu Sawai; Kazuyuki Matsushita; Kazufumi Suzuki; Satoshi Ota; Hideaki Miyauchi; Hisahiro Matsubara; Yukio Nakatani; Fumio Nomura
Journal:  Clin Biochem       Date:  2014-09-28       Impact factor: 3.281

Review 3.  Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.

Authors:  Federica Tosi; Elena Magni; Alessio Amatu; Gianluca Mauri; Katia Bencardino; Mauro Truini; Silvio Veronese; Luciano De Carlis; Giovanni Ferrari; Michele Nichelatti; Andrea Sartore-Bianchi; Salvatore Siena
Journal:  Clin Colorectal Cancer       Date:  2017-01-25       Impact factor: 4.481

Review 4.  Meta-analysis of KRAS mutations and survival after resection of colorectal liver metastases.

Authors:  K W Brudvik; S E Kopetz; L Li; C Conrad; T A Aloia; J-N Vauthey
Journal:  Br J Surg       Date:  2015-07-21       Impact factor: 6.939

5.  Comparison of KRAS mutation analysis of colorectal cancer samples by standard testing and next-generation sequencing.

Authors:  Nishi Kothari; Michael J Schell; Jamie K Teer; Timothy Yeatman; David Shibata; Richard Kim
Journal:  J Clin Pathol       Date:  2014-09       Impact factor: 3.411

6.  Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases.

Authors:  Le-Chi Ye; Tian-Shu Liu; Li Ren; Ye Wei; De-Xiang Zhu; Sheng-Yong Zai; Qing-Hai Ye; Yiyi Yu; Bo Xu; Xin-Yu Qin; Jianmin Xu
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

7.  Clinical pharmacogenomic testing of KRAS, BRAF and EGFR mutations by high resolution melting analysis and ultra-deep pyrosequencing.

Authors:  Emma Borràs; Ismael Jurado; Imma Hernan; María José Gamundi; Miguel Dias; Isabel Martí; Begoña Mañé; Angels Arcusa; José A G Agúndez; Miguel Blanca; Miguel Carballo
Journal:  BMC Cancer       Date:  2011-09-24       Impact factor: 4.430

Review 8.  Are KRAS/BRAF mutations potent prognostic and/or predictive biomarkers in colorectal cancers?

Authors:  Tomoya Yokota
Journal:  Anticancer Agents Med Chem       Date:  2012-02       Impact factor: 2.505

9.  KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study.

Authors:  Serban Negru; Eirini Papadopoulou; Angela Apessos; Dana Lucia Stanculeanu; Eliade Ciuleanu; Constantin Volovat; Adina Croitoru; Stylianos Kakolyris; Gerasimos Aravantinos; Nikolaos Ziras; Elias Athanasiadis; Nikolaos Touroutoglou; Nikolaos Pavlidis; Haralabos P Kalofonos; George Nasioulas
Journal:  BMJ Open       Date:  2014-05-23       Impact factor: 2.692

Review 10.  RAS testing in metastatic colorectal cancer: advances in Europe.

Authors:  J Han J M Van Krieken; Etienne Rouleau; Marjolijn J L Ligtenberg; Nicola Normanno; Scott D Patterson; Andreas Jung
Journal:  Virchows Arch       Date:  2015-11-16       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.